Role of VEGF-A and LRG1 in abnormal angiogenesis associated with diabetic nephropathy
A Zhang, H Fang, J Chen, L He, Y Chen - Frontiers in physiology, 2020 - frontiersin.org
Diabetic nephropathy (DN) is an important public health concern of increasing proportions
and the leading cause of end-stage renal disease (ESRD) in diabetic patients. It is one of the …
and the leading cause of end-stage renal disease (ESRD) in diabetic patients. It is one of the …
Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy
Systemic vascular endothelial growth factor (VEGF) inhibitions can induce worsening
hypertension, proteinuria and glomerular diseases of various types. These agents can also …
hypertension, proteinuria and glomerular diseases of various types. These agents can also …
Systemic adverse events among patients with diabetes treated with intravitreal anti–vascular endothelial growth factor injections
Importance Anti–vascular endothelial growth factor (VEGF) agents are currently the
mainstay of treatment for diabetic retinopathy (DR). Although effective, data on their systemic …
mainstay of treatment for diabetic retinopathy (DR). Although effective, data on their systemic …
Review of intravitreal VEGF inhibitor toxicity and report of collapsing FSGS with TMA in a patient with age-related macular degeneration
Intravitreal vascular endothelial growth factor (VEGF) receptor blockade is used for a variety
of retinal pathologies. These include age-related macular degeneration (AMD), diabetic …
of retinal pathologies. These include age-related macular degeneration (AMD), diabetic …
Do intravitreal anti-vascular endothelial growth factor agents lead to renal adverse events? A pharmacovigilance real-world study
L Jiang, L Peng, Y Zhou, G Chen, B Zhao, M Li… - Frontiers in …, 2023 - frontiersin.org
Purpose Intravitreal vascular endothelial growth factor (VEGF) blockade is essential in many
macular edema diseases treatment. However, intravitreal VEGF treatment has been …
macular edema diseases treatment. However, intravitreal VEGF treatment has been …
[HTML][HTML] Risk of renal damage associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice
MP del Cura, MJC Carballés… - Indian Journal of …, 2023 - journals.lww.com
Purpose: Vascular endothelial growth factor inhibitors (anti-VEGF) have been shown to be
effective in the treatment of diabetic macular edema. However, there is little information …
effective in the treatment of diabetic macular edema. However, there is little information …
Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review
RM Hanna, RS Ahdoot, MS Kim… - Current opinion in …, 2022 - journals.lww.com
Intravitreal vascular endothelial growth factors hypertensio... : Current Opinion in
Nephrology and Hypertension Intravitreal vascular endothelial growth factors hypertension …
Nephrology and Hypertension Intravitreal vascular endothelial growth factors hypertension …
Membranoproliferative glomerulonephritis after intravitreal vascular growth factor inhibitor injections: A case report and review of the literature
G Gan, M Michel, A Max… - British Journal of …, 2023 - Wiley Online Library
Systemic administration of agents that inhibit vascular endothelial growth factor (VEGF) and
therefore vascular proliferation is often used to treat various cancers. However, these agents …
therefore vascular proliferation is often used to treat various cancers. However, these agents …
Intravitreal vascular endothelial growth factor inhibitor use and renal function decline in patients with diabetic retinopathy
SH Ou, CH Yin, TL Chung, HY Chen, CL Chen… - International Journal of …, 2022 - mdpi.com
Adverse renal effects of systemic vascular endothelial growth factor (VEGF) inhibitor
treatment are well documented. We aimed to identify associations between intravitreal VEGF …
treatment are well documented. We aimed to identify associations between intravitreal VEGF …
[HTML][HTML] Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health …
CX Cai, A Nishimura, MG Bowring, E Westlund… - Ophthalmology …, 2024 - Elsevier
Purpose To characterize the incidence of kidney failure associated with intravitreal anti-
VEGF exposure; and compare the risk of kidney failure in patients treated with ranibizumab …
VEGF exposure; and compare the risk of kidney failure in patients treated with ranibizumab …